LESINURAD, A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH ALLOPURINOL: RESULTS FROM A PHASE III STUDY IN GOUT PATIENTS HAVING AN INADEQUATE RESPONSE TO STANDARD OF CARE (CLEAR 2)

被引：6

作者：

Bardin, T. ^{[1
]}

Keenan, R. ^{[2
]}

Khanna, P. ^{[3
]}

Kopicko, J. ^{[4
]}

Fung, M. ^{[4
]}

Bhakta, N. ^{[4
]}

Adler, S. ^{[5
]}

Storgard, C. ^{[4
]}

Baumgartner, S. ^{[4
]}

So, A. ^{[6
]}

机构：

[1] Lariboisiere Hosp, Paris, France

[2] Duke Gout & Crystal Arthropathies Clin, Durham, NC USA

[3] Univ Michigan, Ann Arbor, MI 48109 USA

[4] Ardea Biosci Inc, San Diego, CA USA

[5] AstraZeneca, Gaithersburg, MD USA

[6] Univ Lausanne, Lausanne, Switzerland

来源：

关键词：

D O I：

10.1136/annrheumdis-2015-eular.1238

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

FRI0333

引用

页码：545 / 545

页数：1